Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · lung-landscapes@6

sclc1896_S36.txt

— · cohortMD2

c9eeb590-01cc-5db3-b1aa-57fa3b9f125f

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
cohortMD2
subtype
cohortMD2

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.570
  • INTERFERON_GAMMA_RESPONSE+0.540
  • ALLOGRAFT_REJECTION+0.530
  • INTERFERON_ALPHA_RESPONSE+0.510
  • INFLAMMATORY_RESPONSE+0.490
  • ANGIOGENESIS+0.470
  • COMPLEMENT+0.430
  • IL6_JAK_STAT3_SIGNALING+0.430
  • COAGULATION+0.390
  • APICAL_SURFACE+0.360

Top 10 suppressed

  • G2M_CHECKPOINT-0.330
  • MITOTIC_SPINDLE-0.300
  • E2F_TARGETS-0.290
  • MYC_TARGETS_V1-0.260
  • DNA_REPAIR-0.250
  • MYC_TARGETS_V2-0.240
  • OXIDATIVE_PHOSPHORYLATION-0.200
  • HEME_METABOLISM-0.130
  • PI3K_AKT_MTOR_SIGNALING-0.100
  • PEROXISOME-0.080

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant

#SampleCancer typeSubtypecos similarity
1TCGA-CV-7433-01A-11R-2132-07
head-neck@1
——0.934
2BS_769BDPDB
brain-umap@2
pilocytic astrocytoma—0.926
3SRR1315019
brain-umap@2
GTEX—0.921
4BS_X91K8KMG
brain-umap@2
pilocytic astrocytoma—0.917
5MDT-AP-2921
medullo-epn-umap@date-based
MedMedulloblastoma0.913
6TCGA-JL-A3YW-01A-12R-A239-07
breast-umap@18
—C0.912
7SRR1455171
brain-umap@2
GTEX—0.909
8BS_W97QQYKQ
brain-umap@2
Ganglioglioma—0.909
9MDT-AP-0410
medullo-epn-umap@date-based
MedMedulloblastoma0.905
10s0122206
melanoma-umap@29
——0.902

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 36 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.570Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.540Idelalisib— uncovered
ALLOGRAFT_REJECTION0.530Idelalisib— uncovered
INTERFERON_ALPHA_RESPONSE0.510Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.490Idelalisib— uncovered
ANGIOGENESIS0.470Remibrutinib— uncovered
COMPLEMENT0.430Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.430Inavolisib— uncovered
COAGULATION0.390Binimetinib— uncovered
APICAL_SURFACE0.360Temsirolimus— uncovered
TNFA_SIGNALING_VIA_NFKB0.360Inavolisib— uncovered
IL2_STAT5_SIGNALING0.320Idelalisib— uncovered
MYOGENESIS0.320Inavolisib— uncovered
NOTCH_SIGNALING0.320Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.310Inavolisib— uncovered
APOPTOSIS0.290Idelalisib— uncovered
HYPOXIA0.290Idelalisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.260Remibrutinib— uncovered
KRAS_SIGNALING_UP0.260Inavolisib— uncovered
KRAS_SIGNALING_DN0.240Remibrutinib— uncovered